2Ruiz TJ, Reguero C MD, Arano B Jr, et al. Malignant mixed Mullerian tumors[J]. Clin Transl Oncol, 2006,8 (2):129.
3Baranzelli MC,Pichon F,Gourmel B,et al. High dose ifosfamide at 15g/m^2/eycle: a feasibility study in 10 patients[J]. Bull Cancer,1997,84(2) :141.
4Mardiak J, Salek T, Sycova Mila Z, et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase Ⅱ study[J]. Neoplasma, 2005, 52 (6) :497.
5Gottfried M, Ramlau R, Krzakowski M, et al. Cisplatinbased three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer : final results[J]. J Thorac Oncol, 2008,3 (2) : 152.
6Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in earlystage uterine, sarcoma: a Gynecologic Oncology Group Study [ J ]. Cancer, 1993, 71 (Suppl) : 1702.
7Conrmier JN, Patel SR, Herzog CE. Concurrent ifosfamidebased chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma[J]. Cancer, 2001, 92(6):1550.
8Olah KS, Dunn JA, Gee H. Leiomyosarcoma have a poorer prognosis than mixed mesodermal tumors when adjusting for known prognostic factors : the result of a retrospective study of 423 case of uterine sarcoma[J].ObstetGynecol,1992,99(4) 590.
9Brooks SE, Zhan M, Cote TR, et aL Surveillance, epidemiolo- gy. and end results analysis of 2677 cases of uterine sarcoma 1989-1999[J].GynecolOncol,2004,93(8)-204.
10Major FT, Blessing JA, Silverherg SG, et al. Prognostic factors in early stage uterine sarcoma[J ]. Cancer, 1993,71 (Suppl) 1702.
